We are regularly recognized as leaders in the biotechnology industry. We also receive recognition and awards for our overall performance as a company, our dynamic workplace culture, our contributions to the community and our patient advocacy. Here are some of our most recent achievements.
In December 2017, the Nature Index ranked Roche/Genentech number 2 on its list of the “Top 100 Corporations” based on the output of high-quality science from 2012 to 2016. Roche/Genentech was also the highest-ranked biotech or pharmaceutical company on the list. The Nature Index database regularly tracks the affiliations of high-quality natural science articles and charts publication productivity for institutions and countries.
In November 2017, Genentech was included on the Human Rights Campaign Foundation’s 2018 Corporate Equality Index (CEI) for the 11th consecutive year. Genentech has received a perfect score of 100 percent each year.
The Corporate Equality Index is the national benchmarking tool on corporate policies and practices pertinent to lesbian, gay, bisexual, transgender and queer employees. A total of 609 businesses achieved the distinction of best places to work for LGBTQ equality in the 2018 CEI Report.
In October 2017, Genentech was named one of the "Top Twenty Employers" in biotechnology and pharmaceuticals by Science Careers – produced by the American Association for the Advancement of Science (AAAS) for Science Magazine. This is the 16th consecutive year Genentech has been honored on this list. Genentech has been ranked the #1 company eight times.
The annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries. The 20 companies with the best reputations as employers are listed based on company innovation, social responsibility, employee relations and workplace cultural excellence.
In October 2017, Ann Lee, senior vice president and global head of Pharma Technical Development, was elected a member of the American Academy of Arts & Sciences for her significant contributions to the technical development of more than 21 new medicines and vaccines, the majority of them aimed at preventing or treating cancer.
The American Academy serves the nation as a champion of scholarship, civil dialogue, and useful knowledge. As one of the country's oldest learned societies and independent policy research centers, the Academy convenes leaders from the academic, business, and government sectors to respond to the challenges facing the nation and the world.
In September 2017, FORTUNE Magazine included Genentech on the list of “100 Best Workplaces for Women.” Genentech was recognized for the company’s diversity & inclusion initiatives and high percentage of women in management positions.
Fortune recognizes U.S. companies that are making strides in creating office cultures that cater to the female workforce. This list ranks companies based on the survey results of thousands of women at companies across the country to develop a list of workplaces that go above and beyond for their female employees.
In September 2017, Working Mother magazine named Genentech one of the “100 Best Companies” for working mothers, marking the company’s 24th appearance on the list. Genentech was specifically included in the 2017 list for creating a more flexible workplace for working mothers.
Employers are honored with this award for offering a broad array of support – from flexible work and mentoring to affordable childcare and paid leave – designed to create a culture that allows all employees to flourish both at home and at work. This list ranks companies based on their leave policies, workforce representation, benefits, child care, advancement programs and flexibility policies.
In July 2017, the San Francisco Business Times ranked Genentech number 12 on its list of "Top Bay Area Corporate Philanthropists.” This is the 12th consecutive year Genentech has appeared on the list.
Each year the San Francisco Business Times lists the top 80 companies located in the Bay Area who gave the most back to the community in the past year. Chosen by the San Francisco Business Times staff, the criteria for being considered for this list includes cash donations, volunteer hours, pro bono work and in-kind giving, all of which combine to support creating vibrant and healthy Bay Area neighborhoods.
In June 2017, Computerworld ranked Genentech number 8 among large companies on its list of the “100 Best Places to Work in IT.” This is Genentech’s ninth year on the list. Genentech was also ranked number 3 overall for employee benefits.
To select and rank the top workplaces for IT professionals, Computerworld surveyed more than 450 companies about compensation, promotions, turnover, professional development opportunities, workplace culture, employee benefits and diversity among their IT staff. In a separate employee survey, the IT staff at each company were asked to rate their satisfaction with several key aspects of their jobs and workplaces.
When scoring survey responses, Computerworld weighted each company’s results based on employee ratings of how important each workplace aspect or benefit was to them. Approximately half of the total scoring was based on employee responses, with the remainder based on the survey of the company’s benefits and other programs.
In May 2017, the American Chemical Society inducted Genentech to the Heroes of Chemistry hall of fame for the discovery and development of the first medicine approved for the treatment of metastatic or locally advanced basal cell carcinoma.
The ACS is a nonprofit organization chartered by the U.S. Congress. ACS is the world’s largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.
In May 2017, DiversityInc named Genentech to its list of the “Top 50 Companies for Diversity,” as well as its list of the “Top 12 Companies for Employee Resource Groups.”
DiversityInc’s Top 50 list ranks companies on their diversity management initiatives. The rankings are based on corporate survey submissions from more than 1,600 companies. Companies are evaluated within the context of their own industries on four equally weighted areas: supplier diversity, talent pipeline, equitable talent development and CEO/senior leadership commitment.
In May 2017, Sarah Hymowitz, Vice President and Principal Scientist, Protein Chemistry and Structural Biology, and Christy Oliger, Senior Vice President of BioOncology, Genentech, were named by the San Francisco Business Times as "Most Influential Women in Business." Each year, the San Francisco Business Times honors top women executives at Bay Area corporations and large public, nonprofit and government organizations who make a difference in their companies, industries, and communities.
Sarah is a strong leader for Genentech's research and early development group, and her contributions to the organization have lead to numerous key drug discovery functions benefitting research and early development efforts. Christy has led numerous teams across the commercial and research departments at Genentech, and has been consistently recognized for her skills in managing and uniting complex, global teams to drive success for the organization.
The San Francisco Business Times also named three previous Genentech honorees to its "Forever Influential" Honor Roll, including Sandra Horning, Chief Medical Officer, Global Head of Product Development; Nancy Vitale, Vice President of Human Resources and Regional HR Head, Pharma North America; and Wendy Young, Vice President, Discovery Chemistry.
Previous winners of this award include Carla Boragno, Vice President, Site Services (2016), Amita Joshi, Vice President and Global Head of Clinical Pharmacology (2016), Melissa Starovasnik, Vice President, Protein Sciences (2016), Nancy Vitale, Vice President, Human Resources and Regional Human Resources Head, North America (2015), Wendy Young, Vice President, Small Molecule Discovery Chemistry (2015), and Mary Sliwkowski, Senior Vice President and Global Head of Pharma Technical Regulatory (2014).
In February 2017, FORTUNE magazine ranked Genentech number 12 on its list of the "Top 50 Workplaces for Giving Back." The list recognizes companies that provide their employees with the opportunity to make a positive impact both on and off the job. It is Genentech’s second year on the list.
To identify the honorees, FORTUNE and Great Place to Work surveyed more than 350,000 randomly-selected employees and collected program information from nearly 600 organizations. Employees are asked detailed questions about how proud they are of their impact on the community, the difference they feel they make, amd whether their work has special meaning.
In March 2017, FORTUNE magazine named Genentech one of its “100 Best Companies to Work For” for the 19th consecutive year. Genentech was listed as 6th on this year’s list.
To identify the 100 Best Companies to Work For, FORTUNE continued its partnership with the Great Place to Work Institute (GPTWI) to conduct an extensive employee survey of corporate America, with feedback from more than 230,000 people.
Two-thirds of a company’s score is based on the results of the GPTWI’s Trust Index Survey, which is sent to a random sample of employees from each company. The survey asks questions related to employees’ attitudes about management’s credibility, job satisfaction and camaraderie. The other third is based on responses to the GPTWI’s Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions regarding hiring practices, methods of internal communication, training, recognition programs and diversity efforts.
In November 2016, the Silicon Valley Business Journal ranked Genentech on its list of the “Top 50 Corporate Philanthropists In Silicon Valley.” This is the second consecutive year Genentech has been honored on this list.
Silicon Valley Business Journal’s Top 50 list recognizes companies who went “above and beyond” to support Silicon Valley’s nonprofit organizations. Based on employee volunteer hours and company charitable contributions, the list honored leading companies who helped nonprofit organizations in Silicon Valley in unique and generous ways.
In August 2016, US2020 awarded Genentech with a STEM Mentoring Award in the Excellence in Public-Private Partnerships category. This new award highlights innovative collaborations in STEM mentoring that eliminate barriers for underserved and underrepresented students and communities.
This award serves as a platform to celebrate and encourage exceptional work in the STEM mentoring field, building recognition for STEM mentoring as an important tool in education reform.
Genentech’s Futurelab program partners with the South San Francisco Unified School District to provide employees who mentor students from kindergarten through high school, creating opportunities for students to develop relationships with Genentech professionals.
In Spring 2016, Woman Engineering Magazine included Genentech on its list of “Top 50 Employers” as part of the Reader’s Choice Awards. This is the second consecutive year Genentech has been featured on this list.
Readers of Woman Engineer were asked to name employers who they would most like to work for provide a positive working environment for women.
On February 16, 2016, Vishva Dixit, Ph.D., Vice President, Physiological Chemistry, received the 2016 Trinity College Dublin Dawson Prize in Genetics for his groundbreaking work on cellular death receptor signaling and inflammation.
The Dawson Prize in Genetics has been awarded every two years since 2006 to a geneticist of international prominence as chosen by the faculty of The Smurfit Institute of Genetics at Trinity College Dublin. Previous recipients of the prize include Nobel laureate Sir John Sulston (2006) and Lasker awardee Mary Claire King (2010). The prize was established by a gift from Dr. George Dawson, founder of the Department of Genetics at Trinity College.
On February 8, 2016, Brian D. Kelley, Vice President, BioProcess, U.S. Biologics Pharma Technical Development, Genentech, was elected into the National Academy of Engineering (NAE) for his leadership in bioprocess technology development and developing cost-effective, robust manufacturing processes for numerous life-saving recombinant protein therapeutics. Election to the NAE is among the highest professional distinctions.
Since 1964, the NAE elects new members annually based on their distinguished and continuing achievements in original research. The NAE is a private, nonprofit institution, which honors those who have made outstanding contributions to engineering research, practice, or education. Members serve as the nation’s premier source of independent, expert advice on engineering issues.
In January 2016, Genentech was selected a Top 50 Employer by Equal Opportunity as part of the Reader’s Choice Awards. Equal Opportunity honors this list with top companies who provide a positive working environment for members of minority groups.
Honorees for this award were identified by readers of Equal Opportunity, who were asked to name the employers who they would most like to work or that they believe strive to develop an encouraging environment to ensure success for all employees. Employers included on this list were ranked according to the frequency they were cited by respondents.
In January 2016, MENTOR The National Mentoring Partnership recognized Genentech in its Corporate Mentoring Challenge Honor Roll.
This award acknowledges corporations for their outstanding contributions to advancing quality mentoring opportunities for young people and commitment to the Corporate Mentoring Challenge over the last five years. The Corporate Mentoring Challenge was launched by former First Lady, Michelle Obama, calling on business of all sizes and from all sectors to allow their employees to mentor for short periods of the work day, giving children positive role models and offering employees a way to give back.
In January 2016, Joe Arron, M.D, Ph.D., director of Immunology Discovery, was elected to membership in the American Society of Clinical Investigation (ASCI) for his scientific accomplishments that have changed the therapeutic paradigm for the treatment of asthma and, potentially, other pulmonary diseases.
Election to membership in the ASCI recognizes significant research contributions that extend biological understanding and improve treatment of human diseases. Founded in 1908, the ASCI is one of the nation’s oldest and most respected medical honor societies.
Previous elections include Timothy W. Behrens, Ph.D., senior director, OMNI Human Genetics (2000), Andrew C. Chan, M.D., Ph.D., senior vice president, Research Biology (1999), Teresa Wright, principal medical director, Immunology (1998), Vishva M. Dixit, M.D., vice president, Physiological Chemistry (1996), John B. Lowe, Ph.D., senior director, Pathology (1994), and Eric Brown, M.D., vice president, Immunology and Infectious Diseases (1987).
In November 2015, FORTUNE magazine named Genentech to its inaugural list of the “50 Best Workplaces For Diversity.”
To identify the 50 Best Workplaces for Diversity, FORTUNE and Great Place to Work Institute partnered with Essence Magazine and People en Español to survey more than 600 companies that have made diversity a top priority.
Two-thirds of a company’s score were based on women and minority employees’ evaluations. The remaining third took into account how well represented women and minorities were within the company’s workforce, management, and executive positions, and how positively they experienced their workplace compared to their colleagues. To be considered companies were required to have at least 30 total employees, of which at least 15 percent were women and 15 percent were racial/ethnic minorities, to be considered for the list.
In November 2015, FORTUNE magazine named Genentech to its inaugural list of the “10 Best Workplaces for Asian Americans.”
To identify the 10 Best Workplaces for Asian Americans, FORTUNE relied on survey data collected from minority employees at more than 600 companies for its 50 Best Workplaces for Diversity survey. To be eligible for the list, each company needed stronger representation of Asian Americans within their organization than exists in the United States workforce overall. Companies that met these criteria were then ranked based on how Asian American employees’ scored their workplace experiences in the survey.
In November 2015, Frederic de Sauvage, Ph.D., Vice President, Molecular Oncology, was named a Fellow of the American Association for the Advancement of Science (AAAS) in the section of biological sciences for his distinguished contributions to the field of molecular and translational oncology, particularly for advancing targeted therapies for the treatment of basal cell carcinoma.
Since 1874, the AAAS elects Fellows annually to recognize members for their scientifically or socially distinguished efforts to advance science or its applications. The AAAS is the world’s largest scientific society and is dedicated to advancing science for the benefit of all people.
In October 2015, Genentech was named one of the “Healthiest Companies to Work For in America” by Greatist.com in the Big Companies (5,000-19,999 employees) category. This was Genentech’s third time to be named to the list.
Greatist.com selected companies with not only exemplary health benefits, but with perks that go above and beyond the norm to help employees live their healthiest lives.
In May 2015, Genentech received the Allicense Breakthrough M&A Deal of the Year award from Thomson Reuters for its acquisition of Seragon for a portfolio of investigational next-generation selective estrogen receptor degraders (SERDs). The annual Breakthrough award honors creative partnering efforts for top global deals in M&A and Biopharmaceutical Licensing.
Thomson Reuters Recap analysts examined hundreds of biopharma deals negotiated in 2014 and used both subjective and objective criteria to identify the top five most innovative M&A and Licensing deals. The winners were selected by public vote.
In January 2015, Bruce Roth, Ph.D., senior vice president, Small Molecule Drug Discovery, was awarded the National Academy of Sciences (NAS) Award for Chemistry in Service to Society.
The NAS Award for Chemistry in Service to Society is awarded every two years for contributions to chemistry, either in fundamental science or its application, that clearly satisfy a societal need. Since 1991 the award has recognized the profound benefits of chemistry to society and how advances in chemistry have led to greater economic wealth and a better quality of life. The award is given to chemists working in industry, academia, government, and nonprofit organizations.
In 2015 Minority Engineer Magazine released its “Top 50 Employers” list, ranking Genentech number 31 amongst other top national and global corporations.
Honorees for this award were identified by readers of Minority Engineer, noting which employers they would most like to work or that they believe would provide a positive working environment for members of minority groups.
Sara Kenkare-Mitra, Ph.D., senior vice president, Development Sciences, Genentech Research and Early Development (gRED), was elected to the Institute of Medicine (IOM) in October 2014.
Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. Previous elections include Vishva M. Dixit, M.D., vice president, Physiological Chemistry (2012).
In October 2014, Sandra Horning, chief medical officer and global head of Product Development, was named one of FierceBiotech’s “Top Women in Biotech” for 2014. Sandra has had a distinguished career as an oncologist, an academic and as a leader at Genentech serving in roles across clinical development, product development and medical affairs.
FierceBiotech honors women each year who have risen to the top ranks within their respective fields in areas including drug development, venture capital and marketing. Sandra was recognized for her leadership in the oncology community and her commitment to developing treatments that make a difference for patients.
In September 2014, Anthony P. Adamis, M.D., vice president, Global Head of Ophthalmology, Immunology and Infectious Diseases at Genentech was acknowledged with the prestigious António Champalimaud Vision Award. The award was given to a group of researchers responsible for the development of anti-angiogenic therapy for retinal disease.
The António Champalimaud Vision Award is given for contributions to overall vision research and contributions to the alleviation of visual problems, primarily in developing countries. The work of this year’s recipients covers the entire research process, from the identification of the molecule, to the understanding of its role in retinal-vascular disease in animals and humans, to the evaluation of an inhibitor and its final application in the treatment of affected patients.
In August 2014, Michelle Rohrer, vice president of U.S. Regulatory Affairs, was named by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry. Michelle has an exemplary history in the biotech industry and has served in roles across research and development, quality control and regulatory at Genentech.
The annual PharmaVOICE 100 list is selected from submissions provided by industry executives based on how the nominee has inspired and motivated them, their influence as a corporate leader, and their positive impact on the industry. Michelle was recognized for her ability to innovate as well as develop breakthrough strategies.
Previous employees who have received this honor include Jack Phillips, president and CEO of Roche Diagnostics (2012), Carol Wells, senior director, Genentech (2010) and Maryann Szabo, head of site management, director, North American Regional Monitoring Network (2010).
In July 2014, Genentech was awarded the Beyond the Check Community Impact Award by the San Francisco Business Times. The award recognizes companies committed to making the world a better place, not only in day-to-day work, but by enabling employees to support their communities.
The Beyond the Check Community Impact Award looks beyond monetary donations and focuses on volunteerism and innovation. Genentech was recognized for its efforts to help employees foster deep relationships with the community that result in meaningful change. During Genentech Gives Back Week alone, our employees volunteered over 7,000 hours, serving 47 nonprofits and 154 volunteer projects.
In April 2014, the San Francisco Business Times named Genentech #1 on its annual list of the "Best Places to Work in the Bay Area" in the "extra-large companies" category, defined as having over 1,500 employees. This marks the tenth consecutive year that Genentech has appeared on the list. We have been ranked the #1 company four times.
This list is determined yearly largely on the basis of employee feedback from an online survey from Quantum Workplace, which sent surveys directly to employees of companies that were in consideration. The rankings are numeric, based on Quantum’s scoring process, prioritizing employer practices, culture and values that drive engagement.
In December 2013, Bruce Roth, senior vice president, Small Molecule Drug Discovery, was named by Scrip as three of its 100 Leaders in the healthcare industry. Roche’s Daniel O’Day, chief operating officer, Pharmaceuticals Division was also recognized. The Scrip Intelligence editorial team selected leaders based on their strong impact on the transformation of the healthcare industry.
Bruce Roth was recognized for his leadership and contributions in research and development. Daniel O’Day was honored for his leadership in the pharmaceutical industry.
In December 2013, Ian Clark, chief executive officer of Genentech, accepted The Economist Innovation Award on behalf of Genentech in London. The Economist’s panel of 30 international experts selected Genentech for the Corporate Award, recognizing Genentech for its impressive track record in research and scientific innovation.
The Economist Innovation Awards honor corporations and individuals in the fields of bioscience, computing and telecommunications, energy and the environment, social and economic innovation, process and service innovation, consumer products, a flexible “no boundaries” category, and the corporate use of innovation. Genentech joins previous award winners Google (2012) and Amazon (2011).
In October 2013, the American Federation for Aging Research (AFAR) recognized Michael Varney, executive vice president, Genentech Research and Early Development (gRED), and Andrew Chan, senior vice president, Research Biology, for their work to advance the discovery of medicines for age-related diseases such as cancer, neurologic, autoimmune and inflammatory diseases.
AFAR is dedicated to the advancement of innovative research in the field of healthy aging. For more than 30 years, it has supported physicians and scientists specializing in geriatric medicine and research to better understand how people’s bodies change as they age.
In June 2013, Bruce Roth, senior vice president, Small Molecule Drug Discovery was awarded the 2013 SCI Perkin Medal for his innovation in applied chemistry resulting in outstanding commercial development.
The SCI Perkin Medal is recognized as the highest honor given for outstanding work in applied chemistry in the United States. It commemorates the discovery of the first synthetic dye (the so-called Perkin mauve) by Sir William Henry Perkin in 1856. This discovery was a significant step forward in organic chemistry that led to the birth of a major segment of the chemical industry. The SCI Perkin Medal was first awarded to Sir William at a banquet held by the SCI in New York in 1906. Since then, more than 100 such awards have been given to notable scientists.
Our co-founder, Herb Boyer received the 2007 Perkin Medal for his work on recombinant DNA.
In April 2013, Vishva M. Dixit, M.D., vice president, Physiological Chemistry at Genentech was elected to the Academy in recognition of his distinguished and continuing achievements in original research.
Seven former Genentech employees are also members of the Academy. Genentech co-founder Herb Boyer was elected to the Academy in 1985. Ira Mellman, vice president of Research Oncology at Genentech has been a member since 2011.
Genentech makes life-saving medicine. People make Genentech what it is. This video offers insights into who these people are and what it means to them to be working at Genentech.